Recruiting
Phase 1
Phase 2

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Sponsor:

Effector Therapeutics

Code:

NCT04092673

Conditions

Solid Tumor, Adult

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

eFT226

Sotorasib

Fulvestrant

Abemaciclib

Trastuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information